Table 1.
Characteristics of the study population for incidence analysis
| Characteristic | All participants | Type 2 diabetes, pharmacologically treateda | Type 2 diabetes, non-pharmacologically treatedb |
|---|---|---|---|
| n | 3,227,454 | 36,334 | 39,162 |
| Sex, n (%) | |||
| Male | 1,609,058 (50) | 22,168 (61) | 21,720 (56) |
| Female | 1,618,396 (50) | 14,166 (39) | 17,442 (45) |
| Year of birth | |||
| 1910–1919 | 8685 (0.3) | 13 (0.04) | 15 (0.04) |
| 1920–1929 | 174,081 (5.4) | 1951 (5.4) | 3087 (7.9) |
| 1930–1939 | 261,321 (8.1) | 4824 (13.3) | 7235 (18.5) |
| 1940–1949 | 464,082 (14.4) | 8955 (24.6) | 11,503 (29.4) |
| 1950–1959 | 592,202 (18.3) | 9673 (26.6) | 9670 (24.7) |
| 1960–1969 | 704,276 (21.8) | 7489 (20.6) | 5492 (14.0) |
| 1970–1979 | 716,390 (22.2) | 3163 (8.7) | 2000 (5.1) |
| 1980–1989 | 306,417 (9.5) | 266 (0.7) | 160 (0.4) |
| Education level, n (%) | |||
| ≤10 years | 739,443 (23) | 12,904 (36) | 13,153 (34) |
| 11–13 years | 1,352,663 (42) | 16,551 (46) | 18,532 (47) |
| >13 years | 1,020,357 (32) | 6129 (17) | 7017 (18) |
| No information | 114,991 (4) | 750 (2) | 460 (1) |
| Place of birth, n (%) | |||
| Norway | 2,745,774 (85.1) | 30,714 (84.5) | 34,765 (88.8) |
| Europe (except Norway) | 284,417 (8.8) | 2233 (6.1) | 1702 (4.3) |
| Asia | 117,438 (3.6) | 2303 (6.3) | 1921 (4.9) |
| Africa | 44,061 (1.4) | 731 (2.0) | 513 (1.3) |
| North and Central America | 19,557 (0.6) | 158 (0.4) | 135 (0.3) |
| South America | 14,012 (0.4) | 188 (0.5) | 116 (0.3) |
| Oceania | 2195 (0.07) | 7 (0.02) | 10 (0.03) |
Individuals aged 30–89 years in Norway from 2009 to 2014 were included in the analysis
aAt least one diagnosis of type 2 diabetes and use of non-insulin glucose-lowering medication within 6 months of first being registered with diabetes
bAt least two diagnoses of type 2 diabetes and not treated with glucose-lowering medication within 6 months of first being registered with diabetes